Research programme: cytokine therapeutics - OncoNano Medicine
Latest Information Update: 28 Aug 2024
At a glance
- Originator OncoNano Medicine
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 23 Jul 2020 Early research in Cancer in USA (Parenteral) before July 2020 (OncoNano Medicine pipeline, July 2020)